Literature DB >> 9449268

Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci.

K Sieradzki1, P Villari, A Tomasz.   

Abstract

Of 41 methicillin-resistant coagulase-negative staphylococcal clinical isolates collected during a 5-month period between late 1995 and early 1996, 28 showed tube dilution teicoplanin MICs of 4 to 8 microg/ml which increased to 16 to 32 microg/ml upon prolonged incubation. Cultures of such bacteria were heterogeneous; they contained subpopulations with frequencies of 10(-5) to 10(-4) that could grow on up to 50 microg of teicoplanin per ml. The same cultures were also heterogeneous with respect to susceptibility to vancomycin; while the MICs for the majority of cells were 2 to 4 microg/ml, subpopulations that could grow on 6 to 12 microg of vancomycin per ml were also present at frequencies of 10(-5) to 10(-7). Selective enrichment of such cultures for the resistant subpopulation occurred with relative ease under laboratory conditions. Heterogeneous phenotypes for teicoplanin (but not for vancomycin) susceptibility were also identified in several Staphylococcus epidermidis isolates collected during the preantibiotic era. The addition of half the MIC of teicoplanin inhibited autolysis and caused formation of cellular aggregates which disintegrated to individual bacteria in the stationary phase when the titer of teicoplanin in the medium fell to undetectable levels, indicating removal of the antibiotic from the culture medium by the bacteria.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9449268      PMCID: PMC105463     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1997-08-22       Impact factor: 17.586

2.  Increased production of penicillin-binding protein 2, increased detection of other penicillin-binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus.

Authors:  B Moreira; S Boyle-Vavra; B L deJonge; R S Daum
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

3.  Update: Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1997-09-05       Impact factor: 17.586

4.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

Authors:  K Hiramatsu; H Hanaki; T Ino; K Yabuta; T Oguri; F C Tenover
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

5.  Teicoplanin selects for Staphylococcus aureus that is resistant to vancomycin.

Authors:  D M Shlaes; J H Shlaes
Journal:  Clin Infect Dis       Date:  1995-04       Impact factor: 9.079

6.  Reassessment of the number of auxiliary genes essential for expression of high-level methicillin resistance in Staphylococcus aureus.

Authors:  H de Lencastre; A Tomasz
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

7.  Overproduction of a 37-kilodalton cytoplasmic protein homologous to NAD+-linked D-lactate dehydrogenase associated with vancomycin resistance in Staphylococcus aureus.

Authors:  W M Milewski; S Boyle-Vavra; B Moreira; C C Ebert; R S Daum
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

8.  Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus.

Authors:  K Sieradzki; A Tomasz
Journal:  J Bacteriol       Date:  1997-04       Impact factor: 3.490

9.  Peptidoglycan synthesis and structure in Staphylococcus haemolyticus expressing increasing levels of resistance to glycopeptide antibiotics.

Authors:  D Billot-Klein; L Gutmann; D Bryant; D Bell; J Van Heijenoort; J Grewal; D M Shlaes
Journal:  J Bacteriol       Date:  1996-08       Impact factor: 3.490

10.  THE FINE STRUCTURE OF DIPLOCOCCUS PNEUMONIAE.

Authors:  A TOMASZ; J D JAMIESON; E OTTOLENGHI
Journal:  J Cell Biol       Date:  1964-08       Impact factor: 10.539

View more
  41 in total

1.  Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureus.

Authors:  J R Aeschlimann; E Hershberger; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  Staphylococcus heterogeneously resistant to vancomycin in China and antimicrobial activities of imipenem and vancomycin in combination against it.

Authors:  Wu Benquan; Tang Yingchun; Zhang Kouxing; Zhang Tiantuo; Zhu Jiaxing; Tan Shuqing
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

Review 3.  Molecular detection of antimicrobial resistance.

Authors:  A C Fluit; M R Visser; F J Schmitz
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

4.  Staphylococcus aureus carriage patterns and the risk of infections associated with continuous peritoneal dialysis.

Authors:  Jan Nouwen; Jeroen Schouten; Peter Schneebergen; Susan Snijders; Jolanda Maaskant; Marjan Koolen; Alex van Belkum; Henri A Verbrugh
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

5.  Heterogeneously vancomycin-resistant Staphylococcus epidermidis strain causing recurrent peritonitis in a dialysis patient during vancomycin therapy.

Authors:  K Sieradzki; R B Roberts; D Serur; J Hargrave; A Tomasz
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

6.  Genetic analysis of glycopeptide-resistant Staphylococcus epidermidis strains from bone and joint infections.

Authors:  Julie Cremniter; Valérie Sivadon-Tardy; Charlotte Caulliez; Thomas Bauer; Raphaël Porcher; Alain Lortat-Jacob; Philippe Piriou; Thierry Judet; Philippe Aegerter; Jean-Louis Herrmann; Jean-Louis Gaillard; Martin Rottman
Journal:  J Clin Microbiol       Date:  2012-12-26       Impact factor: 5.948

7.  Molecular Epidemiology of a Vancomycin-Intermediate Heteroresistant Staphylococcus epidermidis Outbreak in a Neonatal Intensive Care Unit.

Authors:  Jasmine Chong; Caroline Quach; Ana C Blanchard; Philippe Guillaume Poliquin; George R Golding; Céline Laferrière; Simon Lévesque
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

8.  Molecular characterization of methicillin-resistant Staphylococcus epidermidis clones: evidence of geographic dissemination.

Authors:  Maria Miragaia; Isabel Couto; Sandro F F Pereira; Karl G Kristinsson; Henrik Westh; Jens O Jarløv; João Carriço; Jonas Almeida; Ilda Santos-Sanches; Hermínia de Lencastre
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

9.  Activities of trovafloxacin and ampicillin-sulbactam alone or in combination versus three strains of vancomycin- intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model.

Authors:  J R Aeschlimann; E Hershberger; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

10.  Vancomycin and oxacillin synergy for methicillin-resistant staphylococci.

Authors:  B E Domaracki; A M Evans; R A Venezia
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.